Glucagon-Like Peptide-1 Receptor
"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).
Descriptor ID |
D000067757
|
MeSH Number(s) |
D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
|
Concept/Terms |
Glucagon-Like Peptide-1 Receptor- Glucagon-Like Peptide-1 Receptor
- Glucagon Like Peptide 1 Receptor
- Peptide-1 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-1
- GLP-1R Receptor
- GLP 1R Receptor
- Receptor, GLP-1R
- GLP1R Protein
- Protein, GLP1R
- GLP-1 Receptor
- GLP 1 Receptor
- Receptor, GLP-1
- GLP1R Receptor
- Receptor, GLP1R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2019 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2021 | 1 | 2 | 3 |
2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023 02; 25(2):407-416.
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
-
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
-
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218.
-
Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic ?-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries. Mol Metab. 2022 01; 55:101392.
-
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
-
A genetic map of the mouse dorsal vagal complex and its role in obesity. Nat Metab. 2021 04; 3(4):530-545.
-
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 05; 2(5):413-431.
-
Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice. Mol Metab. 2019 07; 25:64-72.
-
Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult. J Diabetes Res. 2019; 2019:9426014.